420 with CNW — A Look at the Link Between Marijuana and

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
293
420 with CNW — A Look at the Link Between Marijuana and Inflammation

Inflammation personifies the saying “too much of a good thing is bad.” Despite being one of the body’s first responders in case of infection or physical injury, inflammation also presents a significant risk to health. Acute inflammation is the body’s initial response to either infection or injury, and it is a crucial component of the body’s defense system. Chronic inflammation, on the other hand, happens when the body keeps sending inflammatory cells when there’s no present danger.

A wide variety of medical inflammations including Alzheimer’s disease, asthma, heart disease and cancer can be traced to chronic inflammation. This kind of inflammation usually results in symptoms such as pain in the abdomen, chest and joints, as well as fever, fatigue, headaches, swelling, mood disorders, and skin rashes. Current pharmaceutical medications for chronic inflammation can be quite effective at mitigating the condition, but they tend to cause adverse side effects after long-term use. Unsurprisingly, cannabis has emerged as a viable alternative due to its potent anti-inflammatory properties.

Studies have found that cannabis can function as an effective anti-inflammation agent because of how cannabinoids such as THC and CBD interact with the body. When you ingest cannabis, the cannabinoids interact with the endocannabinoid system (“ECS”), a part of the peripheral nervous system that regulates various functions, including immune response, sleep, appetite and mood. The ECS is filled with CB1 and CB2 receptors that normally respond to naturally produced endocannabinoids similar to the ones in cannabis. By interacting with this system, cannabis helps to inhibit chronic inflammation and mitigates its symptoms.

For instance, a study involving patients afflicted with Crohn’s disease found that 10 out of 11 participants enjoyed some relief from the condition after consuming marijuana. And since cannabis generally has no adverse side effects, the patients were able to avoid the adverse effects that usually result from long-term pharmaceutical drug use.

The controversial plant appears to be effective at easing the symptoms of cancer and cancer treatment, including nausea, insomnia and lack of appetite. HIV patients can also benefit from cannabis treatment as it can alleviate a variety of symptoms and significantly improve the quality of their lives.

Even with the limited research available, cannabis presents an effective alternative to pharmaceuticals for treating inflammatory conditions. Its side effects are inconveniences at best, and the substance can deliver a significant reduction in chronic inflammation. Consult your doctor if you would like to use cannabis to treat an inflammatory condition, and the doctor could also advise you about the best type of product for your needs, including the possibility of using a cannabis beverage made by one of the leading brands such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer


Forte Group Holdings Inc. (FGHFF) Stock Research Links

FGHFF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 77

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 32

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Significant Unusual Options Activity Signals Opportunity in GOOGL

Updated Category News Views 97

Analyzing Recent Options Activity for Alphabet Currently, investors are exhibiting a strong bullish sentiment towards Alphabet (NASDAQ: GOOGL), a trend that is capturing the attention of market participants. Recent observations of public options have revealed significant movements in GOOGL, hinting at potential changes ahead. Recent analyses have uncovered 129 unusual...

Continue Reading
Encore and UKG Introduce Innovative Overtime Savings Program

Updated Category News Views 298

Encore and UKG Join Forces for Employee Financial Wellness Encore, a prominent global leader in event technology and production services, has unveiled an innovative ‘Overtime Savings Program’ in collaboration with UKG, a top provider of HR and workforce management solutions. This remarkable initiative aims to empower Encore's frontline workers, allowing them to save...

Continue Reading
Discover Incredible Returns from Texas Pacific Land Investments

Updated Category News Views 160

The Incredible Growth of Texas Pacific Land Corp Texas Pacific Land Corp (NYSE: TPL) has marked its presence in the market with an outstanding performance over the past 15 years. The company has outshone the market median by an impressive 32.71% annually, which translates to a staggering average annual return of 45.46%. With a current market capitalization nearing $20.51...

Continue Reading
Cypherpunk Q2 2026: Zcash Growth Sparks Market Buzz

Updated Category News Views 76

Cypherpunk Technologies' Stellar Q2 Performance Sit tight, folks, because Cypherpunk Technologies just unleashed a financial update that's got the market buzzing. They've reported a staggering net income of $39.4 million for Q2 2026, quite the turnaround from a $16.6 million loss in the same quarter last year. It's a serious win, no doubt pumped up by their fruitful Zcash...

Continue Reading
Exciting Findings from Aicuris’ Clinical Trials of AIC468

Updated Category News Views 182

Encouraging Insights into AIC468 from Clinical Trials Recently, a notable advancement in medical research has emerged from Aicuris Anti-infective Cures AG regarding its novel treatment, AIC468. This drug is an innovative antisense oligonucleotide targeting the BK virus, particularly in kidney transplant recipients. The first-in-human (FIH) Phase 1 trial has provided...

Continue Reading